Education
About Us
Working with TipRanks
Follow Us
ProKidney (PROK)
NASDAQ:PROK
PROK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.46 - $7.13
Previous CloseN/A
Volume58.77K
Average Volume (3M)2.39M
Market Cap
$676.85M
Enterprise Value$1.13B
Total Cash (Recent Filing)$294.73M
Total Debt (Recent Filing)$3.52M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Nov 18, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding134,993,530
10 Day Avg. Volume1,280,814
30 Day Avg. Volume2,386,318
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.67
Enterprise Value/Revenue2.14K
Enterprise Value/Gross Profit2.14K
Enterprise Value/Ebitda-7.17
Forecast
1Y Price Target
$5.80Price Target Upside152.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical TrialsProKidney Corp has made significant progress in enrolling patients for the Phase 3 PROACT 1 study, with more than half of the patients required for accelerated approval analysis already enrolled.
Financial StabilityProKidney Corp has a cash runway that extends into mid-2027, indicating strong financial support for its operations and development activities.
Regulatory ApprovalThe FDA's alignment with using eGFR as a surrogate endpoint supports an accelerated path for ProKidney's PROACT 1 study, which is a positive development for the company.
Bears Say
Market SentimentA prior pause in the registrational program proved more disruptive than expected, potentially impacting investor confidence.
TimelinesThe timelines to accelerated approval data are longer than originally thought, which may create a sentiment overhang.
Trial RisksAnalyst maintains an Underperform rating with concerns about trial risk and the potentially niche end-market for ProKidney's product.
ProKidney News
PROK FAQ
What was ProKidney’s price range in the past 12 months?
ProKidney lowest stock price was $0.46 and its highest was $7.13 in the past 12 months.
What is ProKidney’s market cap?
ProKidney’s market cap is $676.85M.
When is ProKidney’s upcoming earnings report date?
ProKidney’s upcoming earnings report date is Nov 18, 2025 which is in 73 days.
How were ProKidney’s earnings last quarter?
ProKidney released its earnings results on Aug 12, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.144 by $0.014.
Is ProKidney overvalued?
According to Wall Street analysts ProKidney’s price is currently Undervalued.
Does ProKidney pay dividends?
ProKidney does not currently pay dividends.
What is ProKidney’s EPS estimate?
ProKidney’s EPS estimate is -0.14.
How many shares outstanding does ProKidney have?
ProKidney has 134,993,530 shares outstanding.
What happened to ProKidney’s price movement after its last earnings report?
ProKidney reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.144. Following the earnings report the stock price went up 5.804%.
Which hedge fund is a major shareholder of ProKidney?
Currently, no hedge funds are holding shares in PROK
ProKidney Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.80 (152.17% Upside)
$5.80 (152.17% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 17.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.50%
12-Months-Change
Fundamentals
Return on Equity
4.66%
Trailing 12-Months
Asset Growth
-25.45%
Trailing 12-Months
Company Description
ProKidney
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$5.80
▲(152.17% Upside)
Technical Analysis
Cardiff Oncology
―
Voyager Therapeutics
―
TuHURA Biosciences
―
Genfit SA
―
Design Therapeutics
―
Ownership Overview
82.51% Insiders
6.00% Mutual Funds
0.05% Other Institutional Investors
11.08% Public Companies and
Individual Investors